Skip to main content

Myriad Completes $80M Acquisition of Rules-Based Medicine

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Myriad Genetics today said it has completed its $80 million purchase of Rules-Based Medicine.

RBM will remain based in Austin, Texas and will operate as a wholly owned subsidiary of Myriad. RBM discovers biomarkers for pharmaceutical and biotechnology firms using its multiplex immunoassay technology. It will continue its collaborations with pharma partners in companion diagnostic discovery and carry out internal research projects, Myriad said.

When the deal was announced last month, Myriad said the purchase would expand its product portfolio into new disease areas, including psychiatric disorders, infectious diseases, and inflammatory conditions, and add eight molecular diagnostic product candidates to Myriad's pipeline.

Privately-held Rules-Based Medicine had 2010 revenues of around $25 million and has approximately 160 employees. During Myriad's fiscal fourth quarter ending June 30, RBM is anticipated to contribute $2 million in revenues.

In early morning trading today on the Nasdaq shares of Myriad were down 2 percent at $24.98.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.